Trial Profile
Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jul 2019
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary) ; Etanercept
- Indications Plaque psoriasis
- Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms ACCEPT
- Sponsors Centocor
- 09 Feb 2019 1-year safety data from 12 ustekinumab registrational trials published in the Drug Safety.
- 16 Jun 2018 Results evaluating Cellular and Molecular Changes in response to selective Il-23 Blockade vs Dual Il-12/23 blockade in Psoriasis Skin presented at the 19th Annual Congress of the European League Against Rheumatism
- 03 Aug 2017 Results of pooled analysis of 10 trials (NCT00245960, NCT00111449, NCT00663052, NCT00454584) generating evidence concerning the number of patients dropping out of etanercept trials published in the British Journal of Dermatology